Literature DB >> 3133338

Combined use of alpha-difluoromethylornithine and an inhibitor of S-adenosylmethionine decarboxylase in mice bearing P388 leukemia or Lewis lung carcinoma.

S Nakaike1, K Kashiwagi, K Terao, K Iio, K Igarashi.   

Abstract

The antitumor and antimetastatic effects of alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, combined with an inhibitor of S-adenosylmethionine decarboxylase, either methylglyoxal bis(guanylhydrazone) (MGBG) or ethylglyoxal bis(guanylhydrazone) (EGBG), were studied in mice bearing P388 leukemia or Lewis lung carcinoma. Although EGBG is a more specific inhibitor of polyamine biosynthesis than the widely used MGBG, the antitumor effect of the DFMO-EGBG combination on P388 leukemia-bearing mice was less than that of the DFMO-MGBG combination. The prolongation of survival time by the DFMO(1000 mg/kg)-MGBG(25 mg/kg) combination was 2.65-fold, while that of the DFMO(1000 mg/kg)-EGBG(50 mg/kg) combination was 1.34-fold. When mice were fed a polyamine-deficient diet, stronger antitumor effects were exerted; the prolongation of survival time by the DFMO-MGBG and the DFMO-EGBG combinations was 2.89-fold and 2.03-fold, respectively. The antitumor effect of combined use of the two polyamine antimetabolites with mice on normal and polyamine-deficient diets correlated with a decrease of polyamine charge contents in the tumor cells. The above in vivo results were confirmed clearly in the KB cell culture system. The antimetastatic activity of DFMO on Lewis lung carcinoma-bearing mice was strengthened by the addition of MGBG or EGBG. The antimetastatic activity of the DFMO-MGBG or DFMO-EGBG combination did not parallel the polyamine charge contents in the primary tumor and blood.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3133338      PMCID: PMC5917513          DOI: 10.1111/j.1349-7006.1988.tb01619.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  30 in total

1.  Synergistic antileukemic effect of two polyamine synthesis inhibitors. Host survival and cell-cycle kinetic analysis.

Authors:  A Ask; L Persson; S M Oredsson; O Heby
Journal:  Int J Cancer       Date:  1986-03-15       Impact factor: 7.396

2.  Methyl glyoxal bis(guanylhydrazone) as a potent inhibitor of mammalian and yeast S-adenosylmethionine decarboxylases.

Authors:  H G Williams-Ashman; A Schenone
Journal:  Biochem Biophys Res Commun       Date:  1972-01-14       Impact factor: 3.575

Review 3.  Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions.

Authors:  J M Venditti; R A Wesley; J Plowman
Journal:  Adv Pharmacol Chemother       Date:  1984

4.  Potentiation of antitumor and antimetastatic activities of alpha-difluoromethylornithine by interferon inducers.

Authors:  P S Sunkara; N J Prakash; A L Rosenberger; A C Hagan; P J Lachmann; G D Mayer
Journal:  Cancer Res       Date:  1984-07       Impact factor: 12.701

5.  Formation of a compensatory polyamine by Escherichia coli polyamine-requiring mutants during growth in the absence of polyamines.

Authors:  K Igarashi; K Kashiwagi; H Hamasaki; A Miura; T Kakegawa; S Hirose; S Matsuzaki
Journal:  J Bacteriol       Date:  1986-04       Impact factor: 3.490

Review 6.  Role of polyamines and their antimetabolites in clinical medicine.

Authors:  J Jänne; E Hölttä; A Kallio; K Käpyaho
Journal:  Spec Top Endocrinol Metab       Date:  1983

7.  Antitumor effects of two polyamine antimetabolites combined with mitomycin C on human stomach cancer cells xenotransplanted into nude mice.

Authors:  S Fujimoto; K Igarashi; R D Shrestha; M Miyazaki; K Okui
Journal:  Int J Cancer       Date:  1985-06-15       Impact factor: 7.396

8.  Comparison of inhibitors of S-adenosylmethionine decarboxylase from different species.

Authors:  A E Pegg; G Jacobs
Journal:  Biochem J       Date:  1983-08-01       Impact factor: 3.857

9.  Successful treatment with DL-alpha-difluoromethylornithine in established human small cell variant lung carcinoma implants in athymic mice.

Authors:  G D Luk; M D Abeloff; C A Griffin; S B Baylin
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

10.  Combined therapy of polyamine antimetabolites and antitumor drugs for human gastric cancer xenotransplanted into nude mice.

Authors:  S Fujimoto; K Igarashi; R D Shrestha; M Miyazaki; F Endoh; M Ohta; Y Togawa; K Okui
Journal:  Jpn J Surg       Date:  1986-03
View more
  6 in total

1.  Polyamine transport systems in mammalian cells and tissues.

Authors:  Takeshi Uemura; Eugene W Gerner
Journal:  Methods Mol Biol       Date:  2011

2.  Glucocorticoids and polyamine inhibitors synergize to kill human leukemic CEM cells.

Authors:  Aaron L Miller; Betty H Johnson; Rheem D Medh; Courtney M Townsend; E Brad Thompson
Journal:  Neoplasia       Date:  2002 Jan-Feb       Impact factor: 5.715

3.  Dietary putrescine reduces the intestinal anticarcinogenic activity of sulindac in a murine model of familial adenomatous polyposis.

Authors:  Natalia A Ignatenko; David G Besselsen; Upal K Basu Roy; David E Stringer; Karen A Blohm-Mangone; Jose L Padilla-Torres; Jose M Guillen-R; Eugene W Gerner
Journal:  Nutr Cancer       Date:  2006       Impact factor: 2.900

4.  Polyamine content of Pneumocystis carinii and response to the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine.

Authors:  S Merali; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

Review 5.  Polyamines and their metabolites as diagnostic markers of human diseases.

Authors:  Myung Hee Park; Kazuei Igarashi
Journal:  Biomol Ther (Seoul)       Date:  2013-01       Impact factor: 4.634

6.  Putrescine-stimulated intracellular Ca2+ release for invasiveness of rat ascites hepatoma cells.

Authors:  Y Ashida; A Ueno; Y Miwa; K Miyoshi; H Inoue
Journal:  Jpn J Cancer Res       Date:  1998-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.